{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:50Z","timestamp":1792440590691,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Response to antidepressant therapy is highly variable among individuals. Pharmacogenomic (PGx) testing presents an opportunity to guide drug selection while optimizing therapy outcomes and\/or decreasing the risk for toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A patient with multiple comorbidities, including severe major depressive disorder (MDD), experienced adverse drug events and undesirable response to multiple antidepressant medications (i.e., bupropion, escitalopram, and venlafaxine). A clinical pharmacist assessed significant drug-gene, drug-drug, and drug-drug-gene interactions as well as other clinical factors to provide recommendations for antidepressant therapy optimization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case highlights the importance of PGx testing and the key role of pharmacists in identifying and mitigating drug-related problems and optimizing drug therapy in patients with MDD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03659-4","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:05:07Z","timestamp":1642676707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive\u00a0disorder: a case report"],"prefix":"10.1186","volume":"22","author":[{"given":"N. M.","family":"Del Toro-Pag\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bardolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"7573","key":"3659_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature15817","volume":"526","author":"MV Relling","year":"2015","unstructured":"Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343\u201350.","journal-title":"Nature."},{"key":"3659_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119\u201337.","journal-title":"Annu Rev Med"},{"issue":"10","key":"3659_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2217\/pgs-2019-0047","volume":"20","author":"KT Bain","year":"2019","unstructured":"Bain KT, Matos A, Knowlton CH, McGain D. Genetic variants and interactions from a pharmacist-led pharmacogenomics service for PACE. Pharmacogenomics. 2019;20(10):709\u201318.","journal-title":"Pharmacogenomics."},{"issue":"4","key":"3659_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1586\/17512433.2014.910111","volume":"7","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"3659_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41436-020-00995-w","volume":"23","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Moriarty JP, Swanson KM, et al. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med. 2021;23(3):461\u201370.","journal-title":"Genet Med."},{"issue":"5","key":"3659_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/gim.2017.181","volume":"21","author":"NJ Keeling","year":"2019","unstructured":"Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019;21(5):1224\u201332.","journal-title":"Genet Med"},{"issue":"5","key":"3659_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/cpt.1048","volume":"103","author":"S Volpi","year":"2018","unstructured":"Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, et al. Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects. Clin Pharmacol Ther. 2018;103(5):778\u201386.","journal-title":"Clin Pharmacol Ther"},{"key":"3659_CR8","doi-asserted-by":"publisher","first-page":"575540","DOI":"10.3389\/fphar.2020.575540","volume":"11","author":"RHN van Schaik","year":"2020","unstructured":"van Schaik RHN, M\u00fcller DJ, Serretti A, Ingelman-Sundberg M. Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharmacol. 2020;11:575540.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3659_CR9","first-page":"17","volume":"27","author":"J van der Weide","year":"2006","unstructured":"van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev. 2006;27(1):17\u201325.","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"3659_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/ijms19010233","volume":"19","author":"MK Jha","year":"2018","unstructured":"Jha MK, Trivedi MH. Personalized antidepressant selection and pathway to novel treatments: clinical utility of targeting inflammation. Int J Mol Sci. 2018;19(1):233.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3659_CR11","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"3659_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","volume":"11","author":"R van Westrhenen","year":"2020","unstructured":"van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Juki\u0107 MM. Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry. 2020;11:94.","journal-title":"Front Psychiatry"},{"issue":"6","key":"3659_CR13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00702-009-0229-6","volume":"116","author":"AK Tiwari","year":"2009","unstructured":"Tiwari AK, Souza RP, M\u00fcller DJ. Pharmacogenetics of anxiolytic drugs. J Neural Transm (Vienna). 2009;116(6):667\u201377.","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"3659_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cll.2008.05.006","volume":"28","author":"A Seeringer","year":"2008","unstructured":"Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med. 2008;28(4):619\u201326.","journal-title":"Clin Lab Med"},{"issue":"8","key":"3659_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pgs-2019-0157","volume":"21","author":"L Brown","year":"2020","unstructured":"Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21(8):559\u201369.","journal-title":"Pharmacogenomics."},{"issue":"1","key":"3659_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40246-019-0229-z","volume":"13","author":"K Krebs","year":"2019","unstructured":"Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics. 2019;13(1):39.","journal-title":"Hum Genomics"},{"issue":"16","key":"3659_CR17","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2016.14117","volume":"316","author":"VJ Dzau","year":"2016","unstructured":"Dzau VJ, Ginsburg GS. Realizing the full potential of precision medicine in health and health care. JAMA. 2016;316(16):1659\u201360.","journal-title":"JAMA."},{"issue":"2","key":"3659_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cger.2017.01.009","volume":"33","author":"KT Bain","year":"2017","unstructured":"Bain KT, Knowlton CH, Turgeon J. Medication risk mitigation: coordinating and collaborating with health care systems, universities, and researchers to facilitate the design and execution of practice-based research. Clin Geriatr Med. 2017;33(2):257\u201381.","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"3659_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4140\/TCP.n.2012.24","volume":"27","author":"C Bouwmeester","year":"2012","unstructured":"Bouwmeester C. The PACE program: home-based long-term care. Consult Pharm. 2012;27(1):24\u201330.","journal-title":"Consult Pharm"},{"issue":"5","key":"3659_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4140\/TCP.n.2015.287","volume":"30","author":"AT Blaszczyk","year":"2015","unstructured":"Blaszczyk AT, McGinnis KA, Michaels HN, Nguyen TN. Is it time to call it quits on low-dose quetiapine? Consult Pharm. 2015;30(5):287\u201390.","journal-title":"Consult Pharm"},{"issue":"3","key":"3659_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","volume":"149","author":"JE Tisdale","year":"2016","unstructured":"Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139\u201352.","journal-title":"Can Pharm J (Ott)"},{"issue":"6","key":"3659_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/00005344-200306000-00016","volume":"41","author":"B Drolet","year":"2003","unstructured":"Drolet B, Yang T, Daleau P, Roden DM, Turgeon J. Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol. 2003;41(6):934\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"3659_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/jps.22809","volume":"101","author":"I Plante","year":"2012","unstructured":"Plante I, Vigneault P, Drolet B, Turgeon J. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012;101(2):868\u201378.","journal-title":"J Pharm Sci"},{"issue":"3","key":"3659_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/2045125313510194","volume":"4","author":"M Hasnain","year":"2014","unstructured":"Hasnain M, Vieweg WV, Howland RH, Kogut C, Breden Crouse EL, Koneru JN, et al. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports. Ther Adv Psychopharmacol. 2014;4(3):130\u20138.","journal-title":"Ther Adv Psychopharmacol"},{"key":"3659_CR25","unstructured":"In brief: PPIs and Torsades de Pointes. Med Lett Drugs Ther. 2016;58(1509):153."},{"issue":"8","key":"3659_CR26","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","volume":"65","author":"DA Mrazek","year":"2014","unstructured":"Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014;65(8):977\u201387.","journal-title":"Psychiatr Serv"},{"issue":"9","key":"3659_CR27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamapsychiatry.2014.436","volume":"71","author":"LM Hampton","year":"2014","unstructured":"Hampton LM, Daubresse M, Chang HY, Alexander GC, Budnitz DS. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry. 2014;71(9):1006\u201314.","journal-title":"JAMA Psychiatry"},{"key":"3659_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/bs.apha.2018.03.003","volume":"83","author":"F Corponi","year":"2018","unstructured":"Corponi F, Fabbri C, Serretti A. Pharmacogenetics in psychiatry. Adv Pharmacol. 2018;83:297\u2013331.","journal-title":"Adv Pharmacol"},{"issue":"2","key":"3659_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jac5.1175","volume":"3","author":"S Weinstein","year":"2019","unstructured":"Weinstein S, Carroll JC, Jukic S, Somma Mcgivney M, Klatt P. Perspectives of a pharmacist-run pharmacogenomic service for depression in interdisciplinary family medicine practices. J Am Coll Clin Pharm. 2019;3(2):417\u201324.","journal-title":"J Am Coll Clin Pharm"},{"issue":"2","key":"3659_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2174\/138161210790112728","volume":"16","author":"J Kirchheiner","year":"2010","unstructured":"Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future? Curr Pharm Des. 2010;16(2):136\u201344.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"3659_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cts.12448","volume":"10","author":"ML Rizk","year":"2017","unstructured":"Rizk ML, Zou L, Savic RM, Dooley KE. Importance of drug pharmacokinetics at the site of action. Clin Transl Sci. 2017;10(3):133\u201342.","journal-title":"Clin Transl Sci"},{"issue":"Suppl 3","key":"3659_CR32","first-page":"S235","volume":"36","author":"J Kirchheiner","year":"2003","unstructured":"Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry. 2003;36(Suppl 3):S235\u201343.","journal-title":"Pharmacopsychiatry."},{"issue":"2","key":"3659_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cpt.147","volume":"98","author":"JK Hicks","year":"2015","unstructured":"Hicks JK, Bishop JR, Sangkuhl K, M\u00fcller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127\u201334.","journal-title":"Clin Pharmacol Ther"},{"key":"3659_CR34","volume-title":"Annotation of DPWG Guideline for duloxetine and CYP2D6","author":"PharmGKB","year":"2018","unstructured":"PharmGKB. Annotation of DPWG Guideline for duloxetine and CYP2D6 2018 [updated November 2018. Available from: https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166104942."},{"key":"3659_CR35","volume-title":"Annotation of DPWG Guideline for risperidone and CYP2D6","author":"PharmGKB","year":"2020","unstructured":"PharmGKB. Annotation of DPWG Guideline for risperidone and CYP2D6 2020 [updated May 2020. Available from: https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166104943."},{"key":"3659_CR36","volume-title":"Annotation of DPWG Guideline for sertraline and CYP2C19","author":"PharmGKB","year":"2018","unstructured":"PharmGKB. Annotation of DPWG Guideline for sertraline and CYP2C19 2018 [updated November 2018. Available from: https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166104980."},{"issue":"4","key":"3659_CR37","first-page":"282","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82(4):282\u201390.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"3659_CR38","first-page":"857","volume":"21","author":"P Morissette","year":"2005","unstructured":"Morissette P, Hreiche R, Turgeon J. Drug-induced long QT syndrome and torsade de pointes. Can J Cardiol. 2005;21(10):857\u201364.","journal-title":"Can J Cardiol"},{"issue":"2","key":"3659_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1540-8167.1993.tb01224.x","volume":"4","author":"S Banai","year":"1993","unstructured":"Banai S, Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol. 1993;4(2):206\u201310.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"9","key":"3659_CR40","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.3390\/ijms22094967","volume":"22","author":"L Darakjian","year":"2021","unstructured":"Darakjian L, Deodhar M, Turgeon J, Michaud V. Chronic inflammatory status observed in patients with type 2 diabetes induces modulation of cytochrome P450 expression and activity. Int J Mol Sci. 2021;22(9):4967.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3659_CR41","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/cpt.1496","volume":"106","author":"S Gravel","year":"2019","unstructured":"Gravel S, Chiasson JL, Turgeon J, Grangeon A, Michaud V. Modulation of CYP450 activities in patients with type 2 diabetes. Clin Pharmacol Ther. 2019;106(6):1280\u20139.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03659-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:14:10Z","timestamp":1642677250000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3659"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03659-4","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case study was considered as exempt of review by the Biomedical Research Alliance of New York (BRANY) Internal Review Board (file #21\u201315\u2013105-427).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}